Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Genta, Inc.
Presentations focus on Genasense activity in patients with plasma cell disorders
January 9th, 2005
Genta, Inc., (GNTA) announced that several presentations at the annual meeting of the American Society of Hematology featured use of the company's lead anticancer drug, Genasense (oblimersen sodium) Injection, in patients with blood cancers that involve plasma cells. Investigators from the University of Maryland reported final clinical results and biomarker response information from a phase I-II trial of Genasense plus thalidomide and high-dose dexamethasone in patients with relapsed myeloma. Thirty-three patients were enrolled. Of 30 patients who were evaluable for response, 18 (60%) achieved a major response, including 2 complete responses (CR), 4 near CRs, and 12...
Source: Aging & Elder Health Week (2005-01-09)
|
